<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919409</url>
  </required_header>
  <id_info>
    <org_study_id>TS161-US101</org_study_id>
    <nct_id>NCT03919409</nct_id>
  </id_info>
  <brief_title>First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TS-161 Administered Orally to Healthy Male and Female Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taisho Pharmaceutical R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taisho Pharmaceutical R&amp;D Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, first-in-human study involving single and multiple oral doses of TS-161 in
      healthy male and female participants. The safety, tolerability, pharmacokinetics and
      pharmacodynamics of TS-161 will be evaluated.

      The study includes 3 parts; Part A (single ascending dose: Cohorts 1 to 5) , Part B (single
      dose, cerebrospinal fluid [CSF] collection: Cohort 6), and Part C (multiple ascending dose:
      Cohorts 7 to 9). Participants will be assigned to one of the 9 Cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 3, 2019</start_date>
  <completion_date type="Actual">February 11, 2020</completion_date>
  <primary_completion_date type="Actual">February 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of Adverse Events</measure>
    <time_frame>Parts A and B: Day 1 to Day 8; Part C: Day 1 to Day 17</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - Cmax</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose; Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - Tmax</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose; Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Time to maximum plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - AUC(0-last)</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Area under the plasma concentration versus time curve from time zero to last measurable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - AUC(0-tau)</measure>
    <time_frame>Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Area under the plasma concentration versus time curve over a dosing interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - T1/2</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose; Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - CL/F</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose; Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Apparent clearance following oral administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Plasma Pharmacokinetic Profile - Vd,z/F</measure>
    <time_frame>Parts A and B: Day 1 predose and at multiple time points (up to 48 hours) postdose; Part C: Day 1 predose and at multiple time points (up to 12 hours) postdose, Day 2 to Day 9 predose, Day 10 predose and at multiple time points (up to 48 hours) postdose</time_frame>
    <description>Apparent volume of distribution following oral administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Urine Pharmacokinetic Profile - Ae</measure>
    <time_frame>Part A: Day 1 predose and pooled for multiple intervals (up to 48 hours) postdose; Part C: Day 1 predose and pooled for multiple intervals (up to 48 hours after last dose) postdose</time_frame>
    <description>Amount excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Urine Pharmacokinetic Profile - Fe%</measure>
    <time_frame>Part A: Day 1 predose and pooled for multiple intervals (up to 48 hours) postdose; Part C: Day 1 predose and pooled for multiple intervals (up to 48 hours after last dose) postdose</time_frame>
    <description>Percent of dose excreted in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TS-161 Urine Pharmacokinetic Profile - CLr</measure>
    <time_frame>Part A: Day 1 predose and pooled for multiple intervals (up to 48 hours) postdose; Part C: Day 1 predose and pooled for multiple intervals (up to 48 hours after last dose) postdose</time_frame>
    <description>Renal Clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TS-161 CSF Pharmacokinetic Profile - Cmax</measure>
    <time_frame>Part B: Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Maximum CSF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-161 CSF Pharmacokinetic Profile - Tmax</measure>
    <time_frame>Part B: Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Time to maximum CSF concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-161 CSF Pharmacokinetic Profile - AUC(0-last)</measure>
    <time_frame>Part B: Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Area under the CSF concentration versus time curve from time zero to last</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS-161 CSF Pharmacokinetic Profile - T1/2</measure>
    <time_frame>Part B: Day 1 predose and at multiple time points (up to 24 hours) postdose</time_frame>
    <description>Apparent terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in relative and absolute powers of the delta, theta, alpha, beta and gamma bands using quantitative electroencephalogram (qEEG) compared to placebo</measure>
    <time_frame>Part A: predose and at multiple time points (up to 8 hours) postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Cohort 1: TS-161 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 15 mg or placebo in a fasted condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cohort 2: TS-161 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 50 mg or placebo which will be dosed first in a fasted condition, and then in a fed condition, with a washout period in between 2 dosing. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cohort 3: TS-161 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 100 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cohort 4: TS-161 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 200 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Cohort 5: TS-161 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 400 mg or placebo in a fasted condition. Although planned, all subsequent dose levels after Cohort 1 will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort 6: TS-161 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of TS-161 in a fasted condition. The dose level will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Cohort 7: TS-161 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Cohort 8: TS-161 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Cohort 9: TS-161 TBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily doses of TS-161 or placebo for 10 days in a fed condition. The dose level will be determined based on the results from the preceding cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-161</intervention_name>
    <description>TS-161 capsules</description>
    <arm_group_label>Part A: Cohort 1: TS-161 15 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 2: TS-161 50 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 3: TS-161 100 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 4: TS-161 200 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 5: TS-161 400 mg</arm_group_label>
    <arm_group_label>Part B: Cohort 6: TS-161 TBD</arm_group_label>
    <arm_group_label>Part C: Cohort 7: TS-161 TBD</arm_group_label>
    <arm_group_label>Part C: Cohort 8: TS-161 TBD</arm_group_label>
    <arm_group_label>Part C: Cohort 9: TS-161 TBD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-161 Placebo</intervention_name>
    <description>TS-161 matching placebo capsules</description>
    <arm_group_label>Part A: Cohort 1: TS-161 15 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 2: TS-161 50 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 3: TS-161 100 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 4: TS-161 200 mg</arm_group_label>
    <arm_group_label>Part A: Cohort 5: TS-161 400 mg</arm_group_label>
    <arm_group_label>Part C: Cohort 7: TS-161 TBD</arm_group_label>
    <arm_group_label>Part C: Cohort 8: TS-161 TBD</arm_group_label>
    <arm_group_label>Part C: Cohort 9: TS-161 TBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and female participants between 18 and 55 years of age, inclusive

          -  Body weight ≥ 45 kg

          -  Body Mass Index (BMI) 18 - 30 kg/m^2, inclusive

        Exclusion Criteria:

          -  Significant history or presence of medical disorders or condition capable of
             significantly affecting the absorption, metabolism, or elimination of drugs

          -  History or presence of psychiatric or neurologic disease or condition

          -  History of seizures

          -  Abnormal EEG observed at screening

          -  Abnormal blood pressure

          -  Breast cancer within the past 10 years, or any other malignancies within the past 5
             years

          -  Clinically significant abnormal results in electrocardiogram, blood and urine test

          -  History or presence of liver disease

          -  Participants using medication or supplements within 14 days prior to dosing

          -  Use of N-methyl-D-aspartate (NMDA) receptor modulators (example: dextromethorphan,
             ketamine, amantadine, memantine) within 90 days of screening

          -  Loss of blood or blood products in excess of 450 mL within 60 days prior to screening

          -  Used any investigational drug within 60 days prior to screening

          -  Recent history of alcohol or drug abuse

          -  Any participant who currently uses or has used tobacco products or nicotine-containing
             products (cigarettes, pipes, e-cigarettes, nicotine patches, etc.) for one month or
             more prior to screening

        Exclusion Criteria for Part B only:

          -  Significant abnormalities in lumbar spine

          -  History of clinically significant back pain, back pathology, and/or back injury

          -  History of migraines, and/or frequent, severe headaches

          -  History or presence of significant active bleeding or coagulation disorder or use of
             non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or
             platelet function within 14 days prior to lumbar catheter insertion

          -  Allergy to lidocaine (Xylocaine®) or related drugs

          -  History of adverse reaction to lumbar puncture or epidural procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Taisho Director</last_name>
    <role>Study Director</role>
    <affiliation>Taisho Pharmaceutical R&amp;D Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PAREXEL - Early Phase Clinical Unit-Los Angeles</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TS-161</keyword>
  <keyword>CSF</keyword>
  <keyword>first-in-human</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

